Development of Claudin MAbs for Treating Solid Tumors

用于治疗实体瘤的 Claudin MAb 的开发

基本信息

批准号：
10631161
负责人：
JOSEPH Benjamin RUCKER
金额：
$ 70.93万
依托单位：
INTEGRAL MOLECULAR
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-06-01 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10631161
关键词：
Abbreviations Address Adverse effects Affinity American Amino Acids Antibodies Binding Biological Assay Biopsy Biosensor CD3 Antigens CD34 gene Cancer cell line Cell model Cessation of life Clinic Clinical Data Development Drug Kinetics Endometrial Carcinoma Engineering Exhibits Failure Family member Funding Future Human In Vitro Integral Membrane Protein Isoelectric Point Lead Malignant neoplasm of lung Malignant neoplasm of ovary Malignant neoplasm of pancreas Malignant neoplasm of testis Mass Spectrum Analysis Mediating Membrane Membrane Proteins Modeling Monoclonal Antibodies Mus Patients Peripheral Blood Mononuclear Cell Persons Pharmaceutical Preparations Proteins Proteome Public Health Risk Risk Assessment Safety Small Business Innovation Research Grant Solid Neoplasm Specificity T cell infiltration T-Cell Activation T-Cell Proliferation T-Lymphocyte Temperature Testing Therapeutic Therapeutic Monoclonal Antibodies Tight Junctions Time Tissues Toxic effect Tumor Volume Viscosity Work Xenograft Model Xenograft procedure biopharmaceutical industry cancer cell cancer type candidate selection cell killing claudin 6 clinical development clinical efficacy cytokine cytokine release syndrome differential expression effective therapy efficacy testing experimental study extracellular human disease humanized mouse in vivo light scattering malignant stomach neoplasm manufacture melting neoplastic cell ovarian neoplasm overexpression pre-clinical stem cells therapeutic target therapeutically effective timeline tumor

Abbreviations Address Adverse effects Affinity American Amino Acids Antibodies Binding Biological Assay Biopsy Biosensor CD3 Antigens CD34 gene Cancer cell line Cell model Cessation of life Clinic Clinical Data Development Drug Kinetics Endometrial Carcinoma Engineering Exhibits Failure Family member Funding Future Human In Vitro Integral Membrane Protein Isoelectric Point Lead Malignant neoplasm of lung Malignant neoplasm of ovary Malignant neoplasm of pancreas Malignant neoplasm of testis Mass Spectrum Analysis Mediating Membrane Membrane Proteins Modeling Monoclonal Antibodies Mus Patients Peripheral Blood Mononuclear Cell Persons Pharmaceutical Preparations Proteins Proteome Public Health Risk Risk Assessment Safety Small Business Innovation Research Grant Solid Neoplasm Specificity T cell infiltration T-Cell Activation T-Cell Proliferation T-Lymphocyte Temperature Testing Therapeutic Therapeutic Monoclonal Antibodies Tight Junctions Time Tissues Toxic effect Tumor Volume Viscosity Work Xenograft Model Xenograft procedure biopharmaceutical industry cancer cell cancer type candidate selection cell killing claudin 6 clinical development clinical efficacy cytokine cytokine release syndrome differential expression effective therapy efficacy testing experimental study extracellular human disease humanized mouse in vivo light scattering malignant stomach neoplasm manufacture melting neoplastic cell ovarian neoplasm overexpression pre-clinical stem cells therapeutic target therapeutically effective timeline tumor

展开

项目摘要

ABSTRACT Solid tumors lead to 580,000 deaths annually in the US, and safe and effective therapeutics for many late- stage solid tumors are lacking. Ovarian cancer alone kills 14,000 people each year, and many patients do not respond to currently available treatments. The tight junction protein Claudin 6 (CLDN6) is a validated therapeutic target for many solid tumor types, including ovarian, endometrial, testicular, gastric, and pancreatic cancer. CLDN6 is differentially expressed on cancer cells with almost no expression in normal, healthy tissue. Despite being an attractive target, therapeutic MAbs targeting CLDN6 are difficult to discover due to an absolute need for high specificity. There are 26 human CLDN family members in total and most are broadly expressed and highly conserved, making drug specificity when targeting the CLDNs critically important but especially challenging. The extracellular region of CLDN6 closely resemble the widely expressed CLDN9 (3 amino acids different). The few CLDN6 MAbs discovered by others have demonstrated significant binding to other CLDN family members and most have now been halted in development. Here, we will develop a CLDN6 therapeutic for solid tumors.

抽象的实体瘤每年在美国导致580,000人死亡，许多晚期的安全有效治疗缺乏阶段实体瘤。仅卵巢癌每年就会杀死14,000人，许多患者没有回应当前可用的治疗方法。紧密连接蛋白Claudin 6（Cldn6）是经过验证的许多实体瘤类型的治疗靶标，包括卵巢，子宫内膜，睾丸，胃和胰腺癌症。 CLDN6在癌细胞上差异表达，在正常健康组织中几乎没有表达。尽管是一个有吸引力的靶标，但靶向CLDN6的治疗mAB很难发现绝对需要高特异性。总共有26个人类CLDN家庭成员，大多数是广泛的表达和高度保守，在针对CLDN至关重要的目标时具有药物特异性，但特别具有挑战性。 Cldn6的细胞外区域非常类似于广泛表达的Cldn9（3 氨基酸不同）。其他人发现的少数cldn6 mab已显示出与其他CLDN家庭成员，大多数人现在已经停止了发展。在这里，我们将开发一个Cldn6 实体瘤的治疗性。